Method for determining the relative age of red blood cells

Glycated Hb was measured and compared between five healthy donors (AA), seven non-diabetic and non-transfused homozygous SCD patients (SS) and five non-diabetic, transfused SS patients. The single cell glycation was assessed by flow cytometry using mouse anti-human HbA1c antibody. The inventors demonstrated that glycated Hb was significantly lower in SS patients than in healthy donors (glycated HbS =3.7%, glycated HbA =5.3%, p=0.0025 by DCA and HPLC respectively, and by flow cytometry p=0.0061). In transfused SS patients, results showed that glycated Hb was lower in autologous SS-RBCs than in AA-RBCs by a factor of four (P= 0.008), thus confirming the characterized reduced lifespan of SS RBCs. Glycated Hb levels were measured in RBC sub-populations based on their HbF level (high HbF or low HbF subfractions) in non-transfused SS patients. Single cell glycated Hb assessed by flow cytometry allows to simultaneously estimate the relative age of different RBC sub-populations. This new tool is noninvasive and requires only one single time point measurement.
The present invention relates to a method for in vitro determination of the relative age evaluation of subpopulation of red blood cells by using intracellular glycated hemoglobin measurement by flow cytometry.

Keywords: Diagnostic, Biomarker, Glycated Hb, sickle cell disease (SCD), Flow Cytometry
Patent Application number: European Procedure (Patents) (EPA) - 03 Nov. 2022 - 22 306 656.4 and PCT/EP2023/080678 on 03/11/2023
Inventors:
BARTOLUCCI Pablo,DJOUDER Nassima,HEBERT Nicolas

Reference:

BIO22218-D1

Business Developper
contact
Inserm Transfert
Business Developer
Patent filling date: 2022-11-22

You might also be interested in